
Opinion|Videos|June 20, 2024
KIM-1: Biomarker Analysis in IMmotion010 in RCC
Focusing on renal cell carcinoma, the Oncology Brothers and Toni Choueiri, MD, discuss KIM-1, a biomarker analysis in IMmotion010.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
2
FDA Approves Adjuvant Belzutifan Plus Pembro for Kidney Cancer
3
Generic Larotrectinib Capsules Gain Tentative FDA Approval
4
Dr Hamilton on Tucatinib Maintenance Efficacy in HER2+ Breast Cancer
5







































